120 related articles for article (PubMed ID: 38135130)
1. Dinaciclib inhibits the growth of acute myeloid leukemia cells through either cell cycle-related or ERK1/STAT3/MYC pathways.
Teng CJ; Cheng PT; Cheng YC; Tsai JR; Chen MC; Lin H
Toxicol In Vitro; 2024 Apr; 96():105768. PubMed ID: 38135130
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
3. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.
Rossini E; Tamburello M; Abate A; Zini S; Ribaudo G; Gianoncelli A; Calza S; Valcamonico F; Suardi NR; Mirabella G; Berruti A; Sigala S
Cells; 2024 Feb; 13(5):. PubMed ID: 38474332
[TBL] [Abstract][Full Text] [Related]
4. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR; Halpin M; Corbin DL; Asemelash Y; Sher S; Gordon BK; Whipp EC; Mitchell S; Harrington BK; Orwick S; Benrashid S; Goettl VM; Yildiz V; Mitchell AD; Cahn O; Mims AS; Larkin KTM; Long M; Blachly J; Woyach JA; Lapalombella R; Grieselhuber NR
Exp Hematol Oncol; 2024 Mar; 13(1):27. PubMed ID: 38438856
[TBL] [Abstract][Full Text] [Related]
5. LRRC1 knockdown downregulates MACF1 to inhibit the malignant progression of acute myeloid leukemia by inactivating β-catenin/c-Myc signaling.
Wang Y; Tong H; Wang J; Hu L; Huang Z
J Mol Histol; 2024 Feb; 55(1):37-50. PubMed ID: 38165568
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib.
Hallaj S; Heydarzadeh Asl S; Alian F; Farshid S; Eshaghi FS; Namdar A; Atyabi F; Masjedi A; Hallaj T; Ghorbani A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
Life Sci; 2020 Oct; 259():118150. PubMed ID: 32726663
[TBL] [Abstract][Full Text] [Related]
7. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia.
Gu S; Hou Y; Dovat K; Dovat S; Song C; Ge Z
Exp Hematol Oncol; 2023 Feb; 12(1):23. PubMed ID: 36849955
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
10. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.
Iriyama N; Yuan B; Hatta Y; Takagi N; Takei M
Cancer Cell Int; 2016; 16():37. PubMed ID: 27182202
[TBL] [Abstract][Full Text] [Related]
11. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
12. Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway.
Zhao H; Li S; Wang G; Zhao W; Zhang D; Wang F; Li W; Sun L
Cancer Med; 2019 Aug; 8(9):4348-4358. PubMed ID: 31207099
[TBL] [Abstract][Full Text] [Related]
13. Notopterol-induced apoptosis and differentiation in human acute myeloid leukemia HL-60 cells.
Huang Q; Wang L; Ran Q; Wang J; Wang C; He H; Li L; Qi H
Drug Des Devel Ther; 2019; 13():1927-1940. PubMed ID: 31239643
[No Abstract] [Full Text] [Related]
14. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors.
Abdalla AN; Abdallah ME; Aslam A; Bader A; Vassallo A; Tommasi N; Malki WH; Gouda AM; Mukhtar MH; El-Readi MZ; Alkahtani HM; Abdel-Aziz AA; El-Azab AS
Molecules; 2020 May; 25(9):. PubMed ID: 32397330
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of cervical cancer cells to radiation by the cyclin-dependent kinase inhibitor dinaciclib.
Zhang H; Chu T; Zheng J; Teng Y; Ma R; Zou L; Zhao H
Med Oncol; 2022 Dec; 40(2):68. PubMed ID: 36586018
[TBL] [Abstract][Full Text] [Related]
17. Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells.
Yang J; Lan J; Du H; Zhang X; Li A; Zhang X; Liu Y; Zhang J; Zhang C; Ding Y; Zhang T
Eur J Pharmacol; 2019 Mar; 846():12-22. PubMed ID: 30579933
[TBL] [Abstract][Full Text] [Related]
18. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma.
Shao YY; Li YS; Hsu HW; Lin H; Wang HY; Wo RR; Cheng AL; Hsu CH
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561409
[TBL] [Abstract][Full Text] [Related]
19. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
20. Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways.
Yoon JS; Won YW; Kim SJ; Oh SJ; Kim ES; Kim BK; Cho CG; Choi JH; Park BB; Lee MH; Lee YY
Invest New Drugs; 2012 Dec; 30(6):2284-93. PubMed ID: 22526834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
